In the current study, we established a new cascade targeting delivery system, which uses both angiopep-2 and IP10-EGFRvIIIscFv fusion protein modified nanoparticles (AINPs) to deliver the EGFRvIIIscFv fusion protein into brain malignant glioblastoma cells with accuracy. The gene discussed is CXCL10; the disease is glioblastoma.